Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check41 days agoChange DetectedThe page now indicates that results have been submitted, replacing the previous message that no results were posted.SummaryDifference0.1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check76 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study descriptions and inclusion/exclusion criteria for a clinical trial, while retaining the study's collaborators and revision information.SummaryDifference19%
Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.